Cargando…

Reduced binding activity of vaccine serum to omicron receptor-binding domain

Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination st...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mingzhi, Weng, Shiqi, Wang, Quansheng, Yang, Zibing, Wang, Xiaoling, Yin, Yanjun, Zhou, Qiuxiang, Zhang, Lirong, Tao, Feifei, Li, Yihan, Jia, Mengle, Yang, Lingdi, Xin, Xiu, Li, Hanguang, Kang, Lumei, Wang, Yu, Wang, Ting, Li, Sha, Kong, Lingbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369000/
https://www.ncbi.nlm.nih.gov/pubmed/35967350
http://dx.doi.org/10.3389/fimmu.2022.960195
_version_ 1784766320778149888
author Li, Mingzhi
Weng, Shiqi
Wang, Quansheng
Yang, Zibing
Wang, Xiaoling
Yin, Yanjun
Zhou, Qiuxiang
Zhang, Lirong
Tao, Feifei
Li, Yihan
Jia, Mengle
Yang, Lingdi
Xin, Xiu
Li, Hanguang
Kang, Lumei
Wang, Yu
Wang, Ting
Li, Sha
Kong, Lingbao
author_facet Li, Mingzhi
Weng, Shiqi
Wang, Quansheng
Yang, Zibing
Wang, Xiaoling
Yin, Yanjun
Zhou, Qiuxiang
Zhang, Lirong
Tao, Feifei
Li, Yihan
Jia, Mengle
Yang, Lingdi
Xin, Xiu
Li, Hanguang
Kang, Lumei
Wang, Yu
Wang, Ting
Li, Sha
Kong, Lingbao
author_sort Li, Mingzhi
collection PubMed
description Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination strategy. Here, we expressed monomeric and dimeric receptor-binding domains (RBDs) of the spike protein of prototype SARS-CoV-2 and Omicron variant in E. coli and investigated the reactivity of anti-sera from Chinese subjects immunized with SARS-CoV-2 vaccines to these recombinant RBDs. In 106 human blood samples collected from 91 participants from Jiangxi, China, 26 sera were identified to be positive for SARS-CoV-2 spike protein antibodies by lateral flow dipstick (LFD) assays, which were enriched in the ones collected from day 7 to 1 month post-boost (87.0%) compared to those harvested within 1 week post-boost (23.8%) (P < 0.0001). A higher positive ratio was observed in the child group (40.8%) than adults (13.6%) (P = 0.0073). ELISA results showed that the binding activity of anti-SARS-CoV-2 antibody-positive sera to Omicron RBDs dropped by 1.48- to 2.07-fold compared to its homogeneous recombinant RBDs. Thus, our data indicate that current SARS-CoV-2 vaccines provide restricted humoral protection against the Omicron variant.
format Online
Article
Text
id pubmed-9369000
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93690002022-08-12 Reduced binding activity of vaccine serum to omicron receptor-binding domain Li, Mingzhi Weng, Shiqi Wang, Quansheng Yang, Zibing Wang, Xiaoling Yin, Yanjun Zhou, Qiuxiang Zhang, Lirong Tao, Feifei Li, Yihan Jia, Mengle Yang, Lingdi Xin, Xiu Li, Hanguang Kang, Lumei Wang, Yu Wang, Ting Li, Sha Kong, Lingbao Front Immunol Immunology Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination strategy. Here, we expressed monomeric and dimeric receptor-binding domains (RBDs) of the spike protein of prototype SARS-CoV-2 and Omicron variant in E. coli and investigated the reactivity of anti-sera from Chinese subjects immunized with SARS-CoV-2 vaccines to these recombinant RBDs. In 106 human blood samples collected from 91 participants from Jiangxi, China, 26 sera were identified to be positive for SARS-CoV-2 spike protein antibodies by lateral flow dipstick (LFD) assays, which were enriched in the ones collected from day 7 to 1 month post-boost (87.0%) compared to those harvested within 1 week post-boost (23.8%) (P < 0.0001). A higher positive ratio was observed in the child group (40.8%) than adults (13.6%) (P = 0.0073). ELISA results showed that the binding activity of anti-SARS-CoV-2 antibody-positive sera to Omicron RBDs dropped by 1.48- to 2.07-fold compared to its homogeneous recombinant RBDs. Thus, our data indicate that current SARS-CoV-2 vaccines provide restricted humoral protection against the Omicron variant. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9369000/ /pubmed/35967350 http://dx.doi.org/10.3389/fimmu.2022.960195 Text en Copyright © 2022 Li, Weng, Wang, Yang, Wang, Yin, Zhou, Zhang, Tao, Li, Jia, Yang, Xin, Li, Kang, Wang, Wang, Li and Kong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Mingzhi
Weng, Shiqi
Wang, Quansheng
Yang, Zibing
Wang, Xiaoling
Yin, Yanjun
Zhou, Qiuxiang
Zhang, Lirong
Tao, Feifei
Li, Yihan
Jia, Mengle
Yang, Lingdi
Xin, Xiu
Li, Hanguang
Kang, Lumei
Wang, Yu
Wang, Ting
Li, Sha
Kong, Lingbao
Reduced binding activity of vaccine serum to omicron receptor-binding domain
title Reduced binding activity of vaccine serum to omicron receptor-binding domain
title_full Reduced binding activity of vaccine serum to omicron receptor-binding domain
title_fullStr Reduced binding activity of vaccine serum to omicron receptor-binding domain
title_full_unstemmed Reduced binding activity of vaccine serum to omicron receptor-binding domain
title_short Reduced binding activity of vaccine serum to omicron receptor-binding domain
title_sort reduced binding activity of vaccine serum to omicron receptor-binding domain
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369000/
https://www.ncbi.nlm.nih.gov/pubmed/35967350
http://dx.doi.org/10.3389/fimmu.2022.960195
work_keys_str_mv AT limingzhi reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT wengshiqi reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT wangquansheng reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT yangzibing reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT wangxiaoling reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT yinyanjun reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT zhouqiuxiang reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT zhanglirong reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT taofeifei reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT liyihan reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT jiamengle reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT yanglingdi reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT xinxiu reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT lihanguang reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT kanglumei reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT wangyu reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT wangting reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT lisha reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain
AT konglingbao reducedbindingactivityofvaccineserumtoomicronreceptorbindingdomain